These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15825026)

  • 1. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study.
    Dominguez A; Salleras L; Fedson DS; Izquierdo C; Ruiz L; Ciruela P; Fenoll A; Casal J
    Clin Infect Dis; 2005 May; 40(9):1250-7. PubMed ID: 15825026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
    Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
    Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
    Domínguez A; Ciruela P; García-García JJ; Moraga F; de Sevilla MF; Selva L; Coll F; Muñoz-Almagro C; Planes AM; Codina G; Jordán I; Esteva C; Hernández S; Soldevila N; Cardeñosa N; Batalla J; Salleras L
    Vaccine; 2011 Nov; 29(48):9020-5. PubMed ID: 21939724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.
    Barricarte A; Castilla J; Gil-Setas A; Torroba L; Navarro-Alonso JA; Irisarri F; Arriazu M
    Clin Infect Dis; 2007 Jun; 44(11):1436-41. PubMed ID: 17479939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.
    Vila-Corcoles A; Ochoa-Gondar O; Guzmán JA; Rodriguez-Blanco T; Salsench E; Fuentes CM;
    BMC Infect Dis; 2010 Mar; 10():73. PubMed ID: 20298596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults.
    Benin AL; O'Brien KL; Watt JP; Reid R; Zell ER; Katz S; Donaldson C; Parkinson A; Schuchat A; Santosham M; Whitney CG
    J Infect Dis; 2003 Jul; 188(1):81-9. PubMed ID: 12825175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study.
    Farr BM; Johnston BL; Cobb DK; Fisch MJ; Germanson TP; Adal KA; Anglim AM
    Arch Intern Med; 1995 Nov; 155(21):2336-40. PubMed ID: 7487259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.
    Shapiro ED; Berg AT; Austrian R; Schroeder D; Parcells V; Margolis A; Adair RK; Clemens JD
    N Engl J Med; 1991 Nov; 325(21):1453-60. PubMed ID: 1944423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.
    Peñaranda M; Falco V; Payeras A; Jordano Q; Curran A; Pareja A; Samperiz G; Dalmau D; Ribera E; Riera M
    Clin Infect Dis; 2007 Oct; 45(7):e82-7. PubMed ID: 17806042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological responses to pneumococcal vaccine in frail older people.
    Ridda I; Macintyre CR; Lindley R; Gao Z; Sullivan JS; Yuan FF; McIntyre PB
    Vaccine; 2009 Mar; 27(10):1628-36. PubMed ID: 19100304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia.
    Andrews RM; Counahan ML; Hogg GG; McIntyre PB
    Vaccine; 2004 Nov; 23(2):132-8. PubMed ID: 15531029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005.
    Bliss SJ; Larzalere-Hinton F; Lacapa R; Eagle KR; Frizzell F; Parkinson A; Reid R; Craig M; Santosham M; O'Brien KL
    Arch Intern Med; 2008 Apr; 168(7):749-55. PubMed ID: 18413558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly.
    Domínguez A; Izquierdo C; Salleras L; Ruiz L; Sousa D; Bayas JM; Nebot M; Varona W; Celorrio JM; Carratalà J;
    Eur Respir J; 2010 Sep; 36(3):608-14. PubMed ID: 20075048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
    Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
    Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An emergency department-based vaccination program: overcoming the barriers for adults at high risk for vaccine-preventable diseases.
    Rimple D; Weiss SJ; Brett M; Ernst AA
    Acad Emerg Med; 2006 Sep; 13(9):922-30. PubMed ID: 16902048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.